医学
靶向治疗
肿瘤科
胶质瘤
鉴定(生物学)
突变
内科学
癌症研究
生物信息学
癌症
基因
遗传学
生物
植物
作者
Appaji Rayi,Iyad Alnahhas,Shirley Ong,Pierre Giglio,Vinay K. Puduvalli
标识
DOI:10.1007/s11864-021-00901-9
摘要
Molecular heterogeneity has confounded attempts to target individual pathways in brain tumors. However, gliomas with BRAF mutations have been identified as being uniquely vulnerable to targeted therapies. Such mutations are predominantly seen in brain tumors of the adolescent and young adult population. Given that accurate and timely identification of such mutations is essential for offering appropriate treatment, treatment centers should offer both immunohistochemical and sequencing methods for detection of these mutations to guide treatment. Additional studies of these tumors at recurrence would also allow identification of breakthrough resistance mechanisms that may also be targetable for treatment. Due to the relative rarity of these tumors, multicenter collaborative studies will be essential in achieving long term control of these tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI